Caribou Q2 net loss $29.5M; CB-010 shows 94% ORR; cash runway into Q4 2025

Caribou Biosciences, Inc.

Net loss of $29.5M for Q2 2023 versus $26.7M in Q2 2022; R&D expenses $26.5M.
Cash, equivalents, and marketable securities $292.5M at June 30, 2023; plus $134.6M from July public offering extends runway into Q4 2025.
CB-010 ANTLER trial: 94% ORR (15/16) and 69% CR (11/16) in dose escalation; enrolling second-line LBCL expansion.
Pfizer invested $25M in common stock on June 30, 2023; proceeds to advance CB-011.
Plan to share FDA feedback on CB-010 pivotal trial by YE 2023; initial dose expansion data in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported second quarter of 2023 results: revenue $3.8 million.

Period: second quarter of 2023
Revenue: $3.8 million
Result: reported results

Exact text from the filing

will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.8 million for the three months ended June 30, 2023, compared to $4.2 million for the same period 2022. The decrease was primarily due to a reduction in revenue recognized under the AbbVie

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.